



D a t a s u p p o r t i n g c o m m u n i t y h e a l t h c a r e

Communique

January 2001

A Mayo Reference Services Publication

2000 Index

FEATURE ARTICLES

Application of LightCycler PCR in the Clinical
Microbiology Laboratory 7/00

Biochemical Genetics Laboratory 5/00

The Challenges of Testing for Cryoglobulins 3/00

Customer Service in the New Millennium 1/00

Effects of 4 Hand-Drying Methods for Removing
Bacteria from Washed Hands:
A Randomized Trial 12/00

Enhanced Estradiol Improves Testing Options. 3/00

Fetal Fibronectin: Bedside and In-house Testing
for Prediction of Preterm Labor 2/00

To Flow or Not to Flow: The Appropriate
Laboratory Utilization of Flow
Cytometric Immunophenotyping. 11/00

The Ongoing Battle with Hepatitis C. 4/00

Quality Management Principles: Corrective
versus Preventive Action 10/00

Ruling Out Narcolepsy 6/00

Universal Leukoreduction: Are the Potential
Benefits Worth the Cost?. 8/00

The Utilization of Human Papillomavirus Typing
in the Early Detection and Prevention of
Cervical Cancer 9/00

OTHER ARTICLES

Requesting Test Results – What You May Be
Asked To Provide 2/00

Exceptional Handling 7/00

FOR YOUR INFORMATION

Biochemical Genetics Test Offerings. 5/00

Exceptional Handling 7/00

NEW TEST ANNOUNCEMENTS

Acylcarnitines, Quantitative, Plasma 9/00

Antimicrobial Susceptibility (MIC),
Mycobacterium Avium Complex 9/00

C-reactive Protein, High-Sensitivity 7/00

C2 (Second Component of Complement),
Functional, Serum 8/00

Carbohydrate Deficient Transferrin, Serum 12/00

Culture, Vancomycin-Resistant Enterococcus
(VRE) Screen 3/00

Denatorubral-Pallidoluyasain Atrophy 7/00

Drugs of Abuse Screen, Meconium 9/00

Fatty Acid Profile 11/00

Fluorescence In Situ Hybridization (FISH) for
CCND1/IgH for Mantle Cell Lymphoma 12/00

Fluorescence In Situ Hybridization (FISH) for
Detection of Her-2/neu Amplification
Associated with Breast Cancer. 6/00

Fluorescence In Situ Hybridization (FISH) for
Urothelial Cancer, Urine. 7/00

Fluorescence In Situ Hybridization (FISH) With
TEL and AML1 for Acute Lymphocytic
Leukemia, Blood or Bone Marrow 9/00

Hepatitis B Viral DNA Assay (HBV-DNA),
Quantitative, Serum 11/00

Hepatitis C Antibody (Anti-HCV)
(Reflex to RIBA™), Serum 10/00

Hepatitis C Antibody (Anti-HCV)
(Reflex to HCV RNA by PCR), Serum 10/00

Herpes Simplex Virus DNA Detection by PCR,
Genital. 6/00

Herpes Simplex Virus and Varicella-Zoster
Virus DNA Detection by PCR, Dermal. 6/00

Human Herpesvirus-8 Antibodies, IgG, Serum 9/00

Hypoglycemic Agent Screen, Serum 12/00

21-Hydroxylase Antibodies, Serum 7/00

LDL Subfractionation, Plasma. 5/00

Levofloxacin, Antimicrobial Assay 5/00

Methylmalonic Acid (MMA), Amniotic Fluid. 9/00

Multicolored (M-FISH) for Congenital and
Neoplastic Disorders. 12/00

Myeloma Cells, Blood 5/00

Narcolepsy Associated Antigen, Blood 6/00

NTx Telopeptide, Urine 9/00

PSA Screening, Serum 6/00

Rapamycin (Sirolimus), Blood 5/00

Sulfate, Urine. 5/00

Supersaturation Profile, Urine 5/00

Troponin T, Serum 9/00

TEST UPDATES

Acylglycines, Urine 1/00

Adrenocorticotrophic Hormone 7/00

Allergen Panel Components 3/00

Amino Acids Quantitative Ion-Exchange, Plasma	2/00	Hereditary Hemochromatosis Gene Analysis, Blood	12/00
Amino Acids Quantitative Ion-Exchange, Urine	2/00	Histamine, 24-Hour Collection, Urine	8/00
Amylase, Pancreatic, Body Fluid	4/00	Histamine, Plasma	1/00
Amylase, Pancreatic, Serum	4/00	Histamine, Random Collection, Urine	8/00
Angiotensin Converting Enzyme, Serum	4/00	Homovanillic Acid Method	10/00
Antimicrobial Susceptibility, Nocardia Species	1/00	Human Immunodeficiency Virus-1 (HIV-1) Antibody Method Change	11/00
11 Beta-Prostaglandin F2 Alpha, Urine	3/00	25-Hydroxyvitamin D	6/00
Cancer Antigen 125 (CA125), Serum	12/00	Immunology Assays Method Change	11/00
Change in Billing for Galactose-1 Phosphate Uridyltransferase Testing	11/00	Insulin-Like Growth Factor 1	10/00
Changes in Billing for Leukemia/Lymphoma Immunophenotyping by Flow Cytometry Tissue Specimens	11/00	Nitrogen, Total, Urine	8/00
Chain-of-Custody Testing	12/00	Nortriptyline, Plasma	1/00
C1q (Complement Component C1q), Serum	4/00	Organic Acid Analysis in Urine By Gas Chromatography/Mass Spectrometry	11/00
C5 (Fifth Component of Complement), Serum	4/00	Osteocalcin Parathyroid Hormone-Related Peptide (PTHrP), Plasma	1/00
Carnitine, Plasma or Serum	1/00	Phenylalanine, Plasma	2/00
Cholesterol HDL Topiramate	6/00	Prostate-Specific Antigen (PSA) Total and Free, Serum	1/00
Coccidioides Antibody, Spinal Fluid	2/00	Prostatic Acid Phosphatase Method	10/00
Culture, Vancomycin-Resistant Enterococcus (VRE) Screen	3/00	Retinoids, Serum	12/00
Desipramine, Plasma	1/00	Rubeola (Measles) Antibodies, IgG and IgM Method Change	9/00
Epstein Barr Virus (EBV) Detection by Polymerase Chain Reaction (PCR), Spinal Fluid	8/00	Serum Lead Testing Discontinued 11/00 Tacrolimus, Blood	2/00
Fungal Serology Survey, CSF	2/00	Thyroxine-Binding Globulin Topiramate	6/00
Glycated Hemoglobin, Blood	1/00	Troponin T, Serum	12/00
Hemoglobin F, Red Cell Distribution Change	11/00	Tyrosine, Plasma	2/00
Hepatitis B Viral DNA Assay, Quantitative, Serum	12/00		
Hepatitis C Virus Genotyping	10/00		

Communiqué



Editorial Board:
Jane C. Dale, M.D.
Tammy Fletcher
Terry Gorman
Autumn Latimore
Denise Masoner
Anita Workman

Communiqué Staff:
Managing Editor: Denise Masoner
Medical Editor: Jane C. Dale, M.D.

The Communiqué is published by Mayo Reference Services to provide laboratorians with information on new diagnostic tests, changes in procedures or normal values, and continuing medical education programs and workshops.

A complimentary subscription of the Communiqué is provided to Mayo Medical Laboratories' clients.

Mayo Reference Services Communiqué

Stabile Building
150 Third Street SW
Rochester, Minnesota 55902
1-800-533-1710
<http://www.mayo.edu>

© 2001, Mayo Press

MAYO, MAYO CLINIC
and the Mayo triple-shield
logo and Mayo Reference Services
are marks of Mayo Foundation for
Medical Education and Research.

